Lenalidomide Accord (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s activity, leading to the degradation of transcription factors Ikaros and Aiolos, which in turn produces anti‑angiogenic, immunomodulatory, and anti‑proliferative effects against malignant cells.

The dose of Lenalidomide Accord is individualized by the treating physician based on the specific indication, disease stage, renal function, and other patient‑specific factors. Only a qualified prescriber can determine the appropriate regimen.

Lenalidomide is classified as teratogenic and is contraindicated during pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Breastfeeding is not recommended because the drug may be excreted in milk and could harm the infant.

To place an order, submit an enquiry on the Lenalidomide Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class and is a more potent analogue of thalidomide. Compared with thalidomide, lenalidomide generally shows a better safety profile, especially regarding peripheral neuropathy, while offering comparable anti‑myeloma activity.

Store Lenalidomide Accord at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lenalidomide Accord is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to maintain consistent absorption.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or leukopenia that can predispose to infection, and potential embryofetal toxicity. Patients should report any signs of clotting, fever, or unusual bleeding promptly.

Lenalidomide Accord should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with uncontrolled active infections, or those with severe renal impairment unless dose adjustments are made under medical supervision.